— Know what they know.
Not Investment Advice

APGE NASDAQ

Apogee Therapeutics, Inc.
1W: -1.8% 1M: -9.1% 3M: +20.5% YTD: +8.8% 1Y: +104.3%
$81.16
-1.27 (-1.54%)
 
Weekly Expected Move ±4.7%
$74 $77 $81 $85 $89
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 38 · $5.0B mcap · 57M float · 1.54% daily turnover · Short 53% of daily vol

Cash Flow Trends

Operating Cash Flow
-$227M -32.9% ▼
Capital Expenditures
$5M -346.8% ▼
Free Cash Flow
-$233M -35.0% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$11M -144.9% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$40M-$84M-$182M-$256M
Depreciation & Amort.$0$0$189K$1M
Stock-Based Comp.$2M$6M$23M$46M
Change in Working Capital$10M$6M-$2M-$15M
Other Non-Cash Items$11M-$3M-$11M-$4M
Operating Cash Flow-$16M-$75M-$171M-$227M
— Investing Activities —
Capital Expenditures$0-$167K-$1M-$5M
Acquisitions (Net)$0$0$0$0
Investment Purchases$0-$304M-$649M-$642M
Investment Sales$0$30M$350M$468M
Other Investing$0$0$0$0
Investing Cash Flow$0-$274M-$300M-$180M
— Financing Activities —
Net Debt Issuance$0$0$0$0
Stock Repurchased$0$0$0$0
Dividends Paid$0$0$0$0
Other Financing$0$0$2M$0
Financing Cash Flow$168M$315M$495M$396M
Net Change in Cash$152M-$33M$23M-$11M
Cash End of Period$152M$119M$142M$132M
Free Cash Flow-$16M-$75M-$172M-$233M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms